Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we investigated whether baseline serum levels of IL-6 can predict the treatment response of patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors. In our cohort of 125 NSCLC patients, the objective response rate (ORR) and disease control rate (DCR) were significantly higher in those with low IL-6 (<13.1 pg/ml) than those with high IL-6 (ORR 33.9% vs. 11.1%, p=0.003; DCR 80.6% vs. 34.9%, p<0.001). The median progression-free survival was 6.3 months (95% confidence interval [CI], 3.9–8.7) in the low IL-6 group, significantly longer than in the high IL-6 group (1.9 months, 95% CI, 1.6–2.2, p<0.001). The median overall survival in the low IL-6 group was significantly longer than in the high IL-6 group (not reached vs. 7.4 months, 95% CI, 4.8–10.0). Thus, baseline serum IL-6 levels could be a potential biomarker for predicting the efficacy and survival benefit of PD-1/PD-L1 inhibitors in NSCLC.
Abstract
Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we investigated whether baseline serum levels of IL-6 can predict the treatment response of patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors. In our cohort of 125 NSCLC patients, the objective response rate (ORR) and disease control rate (DCR) were significantly higher in those with low IL-6 (<13.1 pg/ml) than those with high IL-6 (ORR 33.9% vs. 11.1%, p=0.003; DCR 80.6% vs. 34.9%, p<0.001). The median progression-free survival was 6.3 months (95% confidence interval [CI], 3.9–8.7) in the low IL-6 group, significantly longer than in the high IL-6 group (1.9 months, 95% CI, 1.6–2.2, p<0.001). The median overall survival in the low IL-6 group was significantly longer than in the high IL-6 group (not reached vs. 7.4 months, 95% CI, 4.8–10.0). Thus, baseline serum IL-6 levels could be a potential biomarker for predicting the efficacy and survival benefit of PD-1/PD-L1 inhibitors in NSCLC.
참고문헌 (36)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
- Topalian SL, "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy", Nat Rev Cancer, 16, pp.275~287 (2016)
- Mitsuhashi A, "Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients", Clin Transl Oncol, 20, pp.966~974 (2018)
- Kim KH, "The first-week proliferative response of peripheral blood PD-1+ CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors", Clin Cancer Res, 25, pp.2144~2154 (2019)
- Kang DH, "Pleural or pericardial metastasis : a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1", PD-L1 inhibitors, 2018, pp.9, 1500~1508
- Kurman JS, "Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy", J Thorac Dis, 10, pp.1124~1128 (2018)
- Valpione S, "Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade", J Transl Med, 16, pp.94~ (2018)
- Hodge DR, "The role of IL-6 and STAT3 in inflammation and cancer", Eur J Cancer, 41, pp.2502~2512 (2005)
- Kitamura H, "Interleukin-6", STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy, 2017, pp.108, 1947~1952
- Chung YC, "Serum interleukin-6 levels reflect the disease status of colorectal cancer", J Surg Oncol, 83, pp.222~226 (2003)
- Nakashima J, "Serum interleukin 6 as a prognostic factor in patients with prostate cancer", Clin Cancer Res, 6, pp.2702~2706 (2000)
- Zhang GJ, "Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma", Anticancer Res, 19, pp.1427~1432 (1999)
- Silva EM, "High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer", PLoS One, 12, pp.e0181125~ (2017)
- Chang CH, "Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy", Int J Cancer, 132, pp.1977~1985 (2013)
- 박하영, "Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression", Tuberculosis and Respiratory Diseases, 82(3), pp.227~233 (2019), 대한결핵및호흡기학회
- Madore J, "PD-L1 expression in melanoma shows marked heterogeneity within and between patients : implications for anti-PD-1", PD-L1 clinical trials, 2015, pp.28, 245~253
- McLaughlin J, "Quantitative assessment of the heterogeneity of pd-l1 expression in non–small-cell lung cancer", JAMA Oncol, 2, pp.46~54 (2016)
- Xing X, "Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients", OncoImmunology, 7, pp.e1356144~ (2017)
- Goodman AM, "Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers", Mol Cancer Ther, 16, pp.2598~2608 (2017)
- Yarchoan M, "Tumor mutational burden and response rate to pd-1 inhibition", N Engl J Med, 377, pp.2500~2501 (2017)
- McGranahan N, "Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade", Science, 351, pp.1463~1469 (2016)
- Voong KR, "Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer", Ann Transl Med, 5, pp.376~ (2017)
- Teng F, "Progress and challenges of predictive biomarkers of anti PD-1", PD-L1 immunotherapy : a systematic review, 2018, pp.414, 166~173
- Yi M, "Biomarkers for predicting efficacy of PD-1", PD-L1 inhibitors, 2018, pp.17, 129~
- Yamazaki N, "Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma", Cancer Sci, 108, pp.1022~1031 (2017)
- Kauffmann-Guerrero D, "Pretherapeutic inflammation status and cytokine profile may predict response to immunotherapy in NSCLC patients", Ann Oncol, 28, pp.xi12~ (2017)
- Hardy-Werbin M, "Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer", OncoImmunology, 8, pp.e1593810~ (2019)
- Sanmamed MF, "Changes in serum interleukin-8(IL-8)levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients", Ann Oncol, 28, pp.1988~1995 (2017)
- Ohno Y, "Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy", Cancer Sci, 108, pp.1959~1966 (2017)
- Kitamura H, "IL-6-STAT3 controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells", Immunity, 23, pp.491~502 (2005)
- Park SJ, "IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation", J Immunol, 173, pp.3844~3854 (2004)
- Liu H, "IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model", Biochem Biophys Res Commun, 486, pp.239~244 (2017)
- Mace TA, "IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer", Gut, 67, pp.320~332 (2018)